{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:44Z","timestamp":1786649924392,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To conduct a meta-analysis of randomized controlled trials (RCTs) on the effects of atropine eye drop in slowing myopia progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A systematic search of relevant articles was done through a computerized search on PubMed, Medline, Cochrane Library, and Google Scholar on June 16, 2022. A supplementary search was done on\n                      <jats:italic toggle=\"yes\">ClinicalTrials.gov<\/jats:italic>\n                      on the same date. After thorough search and analysis, seven relevant RCTs, double-masked with atropine eye drop as intervention arm and placebo as control arm, were selected for meta-analysis. Jadad scoring was used to evaluate the quality of RCTs. The outcome measurements included in the present meta-analysis are mean changes in the spherical equivalent (SE) of myopic error, and mean changes in axial length (AL) during the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      Pooled summary effect size, calculated by random effect model, for SE of myopia progression was 1.08 with 95% confidence interval (CI) (0.31\u20131.86) which was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value = 0.006). Pooled summary effect size, calculated by random effect model, for axial length was \u2212 0.89 with 95% CI (\u22121.48 to \u2212 0.30) which was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In summary, atropine was demonstrated to be effective in controlling myopia progression in children. Both outcome measures, mean SE changes and mean AL elongation responded to atropine intervention compared to placebo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1339_22","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:25:32Z","timestamp":1671607532000},"page":"6668-6677","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of atropine for myopia control in children: A meta-analysis of randomized controlled trials"],"prefix":"10.4103","volume":"11","author":[{"given":"Shalini","family":"Kumari","sequence":"first","affiliation":[{"name":"Ophthalmology, Al Falah School of Medical Sciences and Research Centre, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Anand","sequence":"additional","affiliation":[{"name":"Ophthalmology, Eye 7 Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Neurology, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh C.","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Critical Care and ICU Services, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simant Kumar","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Critical Care, PSRI, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/APO.0000000000000236","article-title":"Epidemiology of myopia","volume":"5","author":"Wu","year":"2016","journal-title":"Asia-Pac J Ophthalmol (Phila)"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4103\/0975-2870.186048","article-title":"Childhood blindness:A priority eye disease","volume":"9","author":"Bhatnagar","year":"2016","journal-title":"Med J Dr DY Patil Univ"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/oby.22917","article-title":"Screen time for children and adolescents during the COVID-19 pandemic","volume":"28","author":"Nagata","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","article-title":"Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia","volume":"134","author":"Tideman","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.OPX.0000159370.66540.34","article-title":"Myopia progression is specified by a double exponential growth function","volume":"82","author":"Thorn","year":"2005","journal-title":"Optom Vis Sci"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00006324-200009000-00007","article-title":"Temporal variations in myopia progression in Singaporean children within an academic year","volume":"77","author":"Tan","year":"2000","journal-title":"Optom Vis Sci"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.exer.2005.08.009","article-title":"The sclera and myopia","volume":"82","author":"Rada","year":"2006","journal-title":"Exp Eye Res"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0002-9394(02)01883-4","article-title":"Pathologic myopia:Where are we now?","volume":"134","author":"Tano","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00006324-198202000-00008","article-title":"Mydriatic and cycloplegic drugs:A review of ocular and systemic complications","volume":"59","author":"Rengstorff","year":"1982","journal-title":"Am J Optom Physiol Opt"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00006324-196508000-00001","article-title":"The effect of atropine on the development of myopia in monkeys","volume":"42","author":"Young","year":"1965","journal-title":"Am J Optom Arch Am Acad Optom"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0161-6420(79)35455-0","article-title":"The effect of atropine on myopia","volume":"86","author":"Bedrossian","year":"1979","journal-title":"Ophthalmology"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(98)00188-7","article-title":"Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form-deprivation myopia","volume":"794","author":"Fischer","year":"1998","journal-title":"Brain Res"},{"key":"R15-20260109","first-page":"1368","article-title":"The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew","volume":"37","author":"Cottriall","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0014-4835(91)90027-C","article-title":"Muscarinic antagonist effects on experimental chick myopia","volume":"52","author":"Stone","year":"1991","journal-title":"Exp Eye Res"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1167\/iovs.17-22562","article-title":"Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of Alpha2A-adrenoceptors in vitro","volume":"59","author":"Carr","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1021\/pr500558y","article-title":"Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics","volume":"13","author":"Barathi","year":"2014","journal-title":"J Proteome Res"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0952523800171184","article-title":"Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick","volume":"17","author":"Schwahn","year":"2000","journal-title":"Vis Neurosci"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41598-016-0002-7","article-title":"Nitric Oxide (NO) mediates the inhibition of form-deprivation myopia by atropine in chicks","volume":"6","author":"Carr","year":"2016","journal-title":"Sci Rep"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/OPX.0000000000000041","article-title":"Nitric oxide synthase inhibitors prevent the growth-inhibiting effects of quinpirole","volume":"90","author":"Nickla","year":"2013","journal-title":"Optom Vis Sci"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta- analyses:The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157488709788186021","article-title":"A general framework for the evaluation of clinical trial quality","volume":"4","author":"Berger","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaapos.2015.04.006","article-title":"Therapeutic effect of atropine 1% in children with low myopia","volume":"19","author":"Yi","year":"2015","journal-title":"J AAPOS"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"e7371","DOI":"10.1097\/MD.0000000000007371","article-title":"Atropine 0.5% eyedrops for the treatment of children with low myopia:A randomized controlled trial","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low concentration atropine for myopia progression (LAMP) study:A randomized, double-blinded, placebo-controlled trial of 0.05, 0.025, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2018","journal-title":"Ophthalmology"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children:A randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India:Multicentric randomized trial","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia:Effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia:Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia:Changes after stopping atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2:Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children:A multi-center placebo-controlled randomized trial in the UK (CHAMP-UK)-study protocol","volume":"104","author":"Azuara-Blanco","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","article-title":"Myopia outcome study of atropine in children (MOSAIC):An investigator-led, double-masked, placebo-controlled, randomized clinical trial protocol","volume":"2","author":"McCrann","year":"2019","journal-title":"HRB Open Res"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ceo.13736","article-title":"Western Australia atropine for the treatment of myopia (WA-ATOM) study:Rationale, methodology and participant baseline characteristics","volume":"48","author":"Lee","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.1999.15.85","article-title":"Effects of different concentrations of atropine on controlling myopia in myopic children","volume":"15","author":"Shih","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"R41-20260109","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia","volume":"21","author":"Yen","year":"1989","journal-title":"Ann Ophthalmol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1339_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:58Z","timestamp":1786647598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1339_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1339_22","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2022-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}